We showed the dose-dependent growth inhibition by alltrans retinoic acid (ATRA) of myeloma cells freshly isolated from patients. ATRA downregulated the cell surface expression of interleukin-6 receptor (IL-6R) and/or glycoprotein (gp) 130. The growth-inhibitory activity of ATRA was well correlated with that of anti-gpl3O antibody in every sample. Furthermore, ATRA inhibited the production of IL-6 from both myeloma cells and marrow stromal cells, and recombinant IL-6 (rlL-6) could partially recover the myeloma cell growth that had been inhibited by ATRA. These data suggest that ATRA may inhibit the proliferation of myeloma cells both by the downregulation of IL-6R and gp130 expression
on myeloma cells and by the inhibition of IL-6 production from myeloma and stromal cells. Prednisolone (PSL) and interferon-gamma (IFN-y) also inhibited the myeloma growth, while their effects were different from those of ATRA on IL-6 R and gp130 expression, IL-6 production, and morphological change. The inhibitory effect of ATRA on myeloma cell proliferation was observed in 10 of l 4 samples obtained from eight patients, which suggests that ATRA may be a potent new therapeutic agent for some myeloma patients.
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of ATRA on freshly isolated myeloma cells. We also showed that this growth inhibition may operate through the inhibition of the IL-6 production from both myeloma cells and stromal cells, and the downregulation of the expression of IL-6R and/or its signal transducer, glycoprotein (gp)l30," on their cell surface.
MATERIALS AND METHODS

Patients. Eight patients with advanced multiple myeloma (patients A through H) (three with extramedullary plasmacytoma [A, B, and E] and one with plasma cell leukemia [C]
) were examined for this study. To obtain highly purified myeloma cells, BM aspiration and tissue biopsy of patients with advanced diseases (stage IIIA or IIIB) were performed for analysis after informed consent was obtained in accordance with policies established by the institutional review board. Early-stage myeloma patients were also examined, but we could not obtain satisfactorily purified myeloma cells. BM samples were obtained from the patients on different days and after chemotherapy or radiation therapy.
Reagents. Recombinant human IL-6 (rIL-6) was provided by Ajinomoto (Kawasaki, Japan). ATRA, retinol (vitamin A), and retinal were purchased from Sigma Chemical (St Louis, MO). Anti-IL-6R MoAb, PM-l ( y l~) , '~ and anti-gpl30 MoAbs, AM64 and gpx22 ( y l~) '~ were generously donated by Tosoh (Kanagawa, Japan). Isotype-matched MoAb, MOPC-21 (yl K), was purchased from Cappel (West Chester, PA), and interferon-gamma (IFN-y) was obtained from Hayashibara Biochemical Laboratories (Okayama, Japan).
Purification of rnyebmu cells. The purification procedure consisted of Iwato's method with some modification." Briefly, myeloma cells were isolated from BM aspirates, surgically removed tumors of plasmacytoma or venopunctured peripheral blood of a patient with plasma cell leukemia, followed by separation with Ficoll-paque density gradient (Pharmacia LKB, Uppsala, Sweden). The mononuclear cells (MNCs) at the interface were rosetted with sheep RBCs (E-rosetting). Non-E-rosetting cells were fractionated on a discontinuous density gradient of Percoll (Pharmacia LKB), which consisted of 2 mL of 90%. 60%. and 45% Percoll solution in a 15-mL tube. The tubes were centrifuged at 550g for 30 minutes at 4°C. Cells that banded at the interface between 60% and 45% were collected. Myeloma cells were morphologically identified by light microscopy after staining with May-Griinwald-Giemsa. The samples with greater than 70% purity were used for analysis in this study (Table I ).
In vitro cell proliferation assay.
Purified myeloma cells were cultured at a density of 1 X lo5 cells/200 pL per well in RPMI-1640 medium (Nikken Bio-Medical Laboratories, Osaka, Japan) supplemented with 10% fetal calf serum for 72 hours on 96-well flatbottomed tissue culture plates (Costar, Cambridge, MA). Cells were Samples were obtained from the patient on different days before and after chemotherapy or radiation therapy. t SI (stimulation index) = 3H-TdR uptake with IL-GfH-TdR uptake without IL-6. *%inhibition = [1-(3H-TdR uptake with ATRAfH-TdR uptake without ATRA)] x 100. cultured in the presence or absence of ATRA, IFN-y, prednisolone (PSL), and rIL-6, and 3H-thymidine (3H-TdR) uptake was assessed by a 16-hour pulse with 18.5 kBq per well of 3H-TdR (370 GBs/ mmol; Dupont, Wilmington, DE) before harvesting. For testing the growth-inhibitory effect of anti-IL-6R MoAb and anti-gpl30 MoAb, cells were cultured with 10 pg/mL PMI, gpx22, or control IgGlK MoAb, and analyzed.
Preparation of stromal cells. BM MNCs prepared as described earlier were cultured at 1 X 106/mL with RPMI-1640 medium supplemented with 10% fetal calf serum and 1 X mol/L 2-mercaptoethanol (2-ME; Nakarai Tesque, Kyoto, Japan) in 24-well culture plates (Costar) for 24 hours. After removal of nonadherent cells, adherent cells onto plastic plates were used as freshly isolated stromal cell fractions for testing E-6 production. A BM stromal cell line was also used for this study. A BM stromal cell line derived from multiple myeloma, " 3-3, was established by transfecting the plasmid for expression of SV40 large T Ag, and was kindly provided by Dr T. Kaisho (Biomedical Research Center, Osaka University). 16 Preparation of culture supernatants and detection of IL-6. Purified myeloma cells were cultured at a density of 1 X 106/mL on 24-well plates for 48 hours with ATRA, IFN-y, or PSL. Freshly isolated stromal cells derived from 1 X lo6 MNCs and a stromal cell line, "3-3, at a density of 1 X lO"/mL were cultured for 48 hours with ATRA, IFN-7, or PSL. IL-6 in the culture supernatant was measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DEL-HA)."
Phenofypic analysis. Cell surface ILdR and gp130 of freshly isolated myeloma cells and of cells cultured with molL ATRA, 100 U/mL IFN-y, or lo-' m o m PSL for 48 hours were identified by biotinylated PM1 and AM64 or gpx22 MoAb, respectively, in conjunction with phycoerythrin-labeled streptavidine. A quantity of 2 X 1 6 cells was incubated with 0.5 mg of antibody for 20 minutes on ice for staining. Isotype-matched MoAb, MOPC-2 1 ( y 1 K), served as the negative control. Flow-cytometric analysis was performed on a FACScan (Becton Dickinson, Mountain View, CA).
RESULTS
Inhibition of myeloma cell growth.
To ascertain the inhibitory effect of ATRA on the growth of myeloma cells, purified myeloma cells from patients were cultured for 72 hours with ATRA from to mom. Representative data (sample 1) are shown in Fig 1. As shown in Fig lA, ATRA inhibited the proliferation of freshly isolated myeloma cells in a dose-dependent manner, and the cell growth was almost completely inhibited at the mom. Because ATRA is metabolized from retinol through retinal stage,18 retinol, retinal, and ATRA were examined for their capability to inhibit the growth of myeloma cells. Figure 1B clearly shows that both retinol and retinal could not inhibit the proliferation of the cells even at a dose of mom. However, ATRA showed a strong inhibitory effect, which suggests that myeloma cell growth inhibition is not a common characteristic of vitamin A derivatives.
To compare the growth-inhibitory effect of ATRA with that of other inhibitory agents, the purified myeloma cells were cultured with the optimal doses of IFN-7 and PSL, as well as ATRA, for 72 hours. FN"y (100 U/mL) and PSL (10" m o m ) inhibited the cell growth less than ATRA did (Fig 1C) .
Modulation ofIL-6R andgpl30 expression by ATRA. Because ATRA was reported to downregulate IL-6R expression on a myeloma cell line," the modulation of IL-6R and gp130 duction from the myeloma cell fractions was examined. The purified myeloma cell fraction was cultured for 48 hours with ATRA, and the amounts of IL-6 in the culture supernatants were detected with the DELFIA method. As shown in Fig 3, mol/L of ATRA inhibited IL-6 production from a myeloma cell fraction (sample 1) by approximately 80%. However, possible contamination of stromal cells in the purified myeloma cell fraction had to be considered. Furthermore, paracrine rather than autocrine regulation of the growth of myeloma cells by IL-6 has been reported.* Therefore, the inhibition of IL-6 production by ATRA was examined in freshly isolated stromal cell fractions and an SV40-transformed stromal cell line, "3-3, which was established from a patient with multiple myeloma. As shown in Fig 4, stromal cell fractions freshly isolated from patients (Fig 4A  and B ) and the stromal cell line (Fig 4C) produced relatively abundant IL-6 during short-term culture. ATRA inhibited L 6 production, while higher concentrations (1 0-4 mol/L) of ATRA were required for inhibition in some cases. The effects of PSL and IFN-y on IL-6 production in the myeloma cell fraction were also examined. As shown in Fig 3, PSL (IO" mol/L) also inhibited the production of 1L-6, whereas IFN-y ( 1 0 0 U/mL) enhanced it. These results suggest that the growth inhibition of myeloma cells by ATRA may be partially caused by the inhibition of IL-6 production from both myeloma cells and stromal cells. rIL-6 partially reactivated ,n?elomu cell growth thut w a s inhibited by ATRA. To confirm that the decrease in L 6 production plays a part in the growth-inhibitory effect of ATRA, we examined whether exogenous TL-6 was able to rescue the myeloma cell growth that had been inhibited by ATRA. I n fact, the growth inhibition by ATRA was partially counteracted by additional rIL-6 as shown in Fig 5 , indicating that the inhibition of IL-6 production by ATRA tnay be partly responsible for the inhibitory effect of ATRA on the proliferation of myeloma cells.
Morphologic arzalysis of cultured n?yeloma cells. Morphologic analysis of myeloma cells was performed before and after the in vitro culture with ATRA, IL-6, PSL, and IFN-y for 48 hours. Cultured cells and their nuclei without any reagent ( Fig  6B) were larger than freshly isolated myeloma cells (Fig 6A) . However, the cells cultured with ATRA ( Fig 6C) were small with a dense nucleus, which suggests that they were dormant, while some of the cells had died. On the other hand, the cells with rlL-6, PSL, or LFN-y appeared to be the same as those without any reagent (Fig 6D, E, and F) . Table 1 summarizes the inhibitory effect of ATRA on the proliferation of 14 myeloma cell samples obtained from eight patients. In addition, Table 1 shows the augmentation of their growth caused by rIL-6. ATRA strongly inhibited the growth of myeloma cells in six of 14 samples, whereas a less inhibitory effect was observed in four samples. In contrast, no inhibitory effect was observed in four samples, and one showed augmented growth by ATRA. These different effects of ATRA were closely related to the growth-inhibitory effect of anti-gp130 MoAb (Fig 7) . The myeloma cells in which proliferation was inhibited by greater than 50% by ATRA showed greater than 30% growth inhibition by anti-gpl30 MoAb. On the other hand, the myeloma cells in which proliferation was inhibited by less than 50% by ATRA showed less than 30% growth inhibition by anti-gpl30 MoAb. More- over, the rate of inhibition by ATRA closely correlated with that by anti-gp130 MoAb (y = 0 . 7 9~ -1 1.2, where y is the percent inhibition by anti-gpl30 MoAb, and x is the percent inhibition by ATRA; r = .78). These data indicate that the inhibitory effect of ATRA on the growth of myeloma cells varied from patient to patient. However, because the inhibitory effect of ATRA closely correlated with that of antigp130 MoAb, growth inhibition of myeloma cells by ATRA may be caused by blocking the growth signal transduction of IL-6.
DISCUSSION
We demonstrated that ATRA inhibited the growth of freshly isolated myeloma cells in vitro. ATRA is a wellknown therapeutic agent that can differentiate APL cells into mature gran~locytes.'~~'~~" APL is often associated with the translocation t( 15; 17) and the gene encoding the retinoic acid receptor-a (RAR-a) maps on chromosome 17q21.'? Because the translocation alters the transacting properties of RAR-a, only a high dose of ATRA can differentiate APL cells into mature granulocytes. 23 In human multiple myeloma, such translocation has not been reported. Therefore, the mechanism of ATRA action on myeloma cells seems to be different from that on APL cells.
To analyze the mechanism of the antiproliferative activity of ATRA on myeloma cells, we examined the effects of ATRA on both the expression of IL-6R and gp130 by myeloma cells, as well as the production of IL-6 by myeloma cells and stromal cells.
In 1991, Sidell et all' showed the antiproliferative activity of ATRA on a myeloma cell line, AFIO, which grew autocrinely in an IL-6-dependent manner. They demonstrated that the antiproliferative activity of ATRA might be a result of the downregulation of ILdR expression on myeloma cells. Their observation is consistent with our result that the expression of IL-6R was downregulated by ATRA in four of nine cases. Furthermore, ATRA also downregulated the expression of gp130 in four of nine cases. In short, IL-6R and/or gp130 expression was partially downregulated by ATRA in seven of nine myeloma samples. Although downregulation of these receptors was also observed in some myeloma cells in which growth was independent of IL-6 by in vitro assay, ATRA could not inhibit their growth. These data suggest that the antiproliferative activity of ATRA may be the result of the downregulation of ILdR and/or gp130 only in the myeloma cases in which growth might be dependent on 1L-6. This idea was also supported by the observation of a strong correlation between the antiproliferative effect of ATRA and that of anti-gp130 MoAb in every sample ( r = .78, P < . 0 0 1 ; Table 1 and Fig 7) . However, the question still remains why the growth stimulation by additional rIL-6 apparently did not correlate with the inhibitory effect of We also showed the inhibition of E -6 production by ATRA in myeloma cell fractions. It is known that E -6 is an autocrine growth factor for myeloma cells,' whereas Klein et a12 reported the paracrine but not autocrine regulation of the growth of myeloma cells by IL-6, which was secreted from the stromal cells in the BM of their patients. Recently, Uchiyama et alZ6 showed that the adhesion of myeloma cell lines to normal BM stromal cells triggered E-6 production by stromal cells, rather than by myeloma cell lines. We showed the inhibition of L -6 production in both freshly isolated BM stromal cells and SV40-transformed BM stro-3045 mal cells established from a patient with multiple myeloma. This suggests that ATRA may inhibit the IL-6 production from stromal cells, as well as myeloma cells. Therefore, even though the purified cell fraction was contaminated with a few stromal cells, ATRA must have inhibited their IL-6 production and ultimately blocked the autocrine and paracrine growth of myeloma cells. Furthermore, the finding that the growth inhibition of myeloma cells by ATRA was partially counteracted by the reconstitution of exogenous rIL-6 through the residual receptors confirmed that some of the growth inhibition by ATRA was caused by the inhibition of IL-6 production. The rest of the growth inhibitiory effect may be caused by the partial downregulation of IL-6R and gp130.
A comparative study of ATRA, PSL, and IFN-y suggested that IFN-y inhibited the growth of freshly isolated myeloma cells by the downregulation of ILdR. Previous reports have presented contradictory data on the modulation of IL-6R expression by IFN-y.27, 28 Portier et a12' demonstrated that IFN-y downregulated IL-6R, whereas Jernberg-Wiklund et a1" maintained it did not. Our data support the former. However, the therapeutic application of IFN-y must be performed carefully, because IFN-y stimulated the IL-6 production from myeloma cells in vitro. PSL showed similar effect to that of ATRA on IL-6 production. The myeloma cells cultured in vitro appeared larger in size and their cytoplasm was more abundant than that of freshly isolated cells, which suggests that the former may have been stimulated by IL-6 secreted from myeloma cells or stromal cells in vitro. The myeloma cells cultured with PSL and IFN-y appeared morphologically identical to the cells cultured with or without rIL-6. However, the myeloma cells cultured with ATRA appeared to be dormant or dead, which suggests that the mechanism of ATRA action may be different from that of PSL or IFN-y.
Generally, retinol is incorporated in target cells and converted to retinoic acid (RA) through the retinal stage.'' This converted RA was shown to inhibit the proliferation and IL-6 production in normal B cells.' However, activated B cells, which possess the receptors for RA, could not convert retinol into RA.29 Our data show that ATRA, but not retinol or retinal, inhibits the growth of myeloma cells. Therefore, it is suggested that retinol may not be converted to RA in myeloma cells such as activated B cells, and that retinol and retinal are not able to inhibit the growth of myeloma cells. We did not analyze the effect of 13-cis RA on myeloma cells, but 13-cis RA may also have an inhibitory effect similar to that of ATRA.
In this report, we showed that ATRA inhibits myeloma cell growth in vitro. ATRA can interfere with the autocrine and paracrine loop of IL-6-dependent myeloma cell growth both by downregulation of ILdR and gp130 expression and by inhibition of IL-6 production. This suggests that ATRA is a potential therapeutic agent for IL-6-dependent myeloma. We analyzed the inhibitory effect of ATRA on myeloma cells only from the patients with advanced disease to obtain highly purified myeloma cells. Thus, we do not know whether myeloma cells from early stages can respond to ATRA. Recently, Vesole et a130 tested the therapeutic efficacy of ATRA in 1 1 myeloma patients in vivo but could not 
